R
Roger S. Lo
Researcher at University of California, Los Angeles
Publications - 112
Citations - 27411
Roger S. Lo is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Melanoma & Vemurafenib. The author has an hindex of 51, co-authored 103 publications receiving 23474 citations. Previous affiliations of Roger S. Lo include University of California & United States Department of Veterans Affairs.
Papers
More filters
Journal ArticleDOI
Tgfbeta signaling in growth control, cancer, and heritable disorders
TL;DR: The author would like to thank S. H. Roan for all her help and members of the Massague laboratory for insightful discussions.
Journal ArticleDOI
Genomic and transcriptomic features of response to anti-pd-1 therapy in metastatic melanoma
Willy Hugo,Jesse M. Zaretsky,Lu Sun,Chunying Song,Blanca Homet Moreno,Siwen Hu-Lieskovan,Beata Berent-Maoz,Jia Pang,Bartosz Chmielowski,Grace Cherry,Elizabeth Seja,Shirley H. Lomeli,Xiangju Kong,Mark C. Kelley,Jeffrey A. Sosman,Douglas B. Johnson,Antoni Ribas,Roger S. Lo +17 more
TL;DR: It is found that overall high mutational loads associate with improved survival, and tumors from responding patients are enriched for mutations in the DNA repair gene BRCA2, suggesting that attenuating the biological processes that underlie IPRES may improve anti-PD-1 response in melanoma and other cancer types.
Journal ArticleDOI
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky,Angel Garcia-Diaz,Daniel Sanghoon Shin,Helena Escuin-Ordinas,Willy Hugo,Siwen Hu-Lieskovan,Davis Y. Torrejon,Gabriel Abril-Rodriguez,Salemiz Sandoval,Lucas Barthly,Justin Saco,Blanca Homet Moreno,Riccardo Mezzadra,Bartosz Chmielowski,Kathleen Ruchalski,I. Peter Shintaku,Phillip J. Sanchez,Cristina Puig-Saus,Grace Cherry,Elizabeth Seja,Xiangju Kong,Jia Pang,Beata Berent-Maoz,Begoña Comin-Anduix,Thomas G. Graeber,Paul C. Tumeh,Ton N. Schumacher,Roger S. Lo,Antoni Ribas +28 more
TL;DR: Acquired resistance to PD-1 blockade immunotherapy in patients with melanoma was associated with defects in the pathways involved in interferon-receptor signaling and in antigen presentation.
Journal ArticleDOI
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian,Hubing Shi,Qi Wang,Xiangju Kong,Richard C. Koya,Hane Lee,Zugen Chen,Mi Kyung Lee,Narsis Attar,Hooman Sazegar,Thinle Chodon,Stanley F. Nelson,Grant A. McArthur,Jeffrey A. Sosman,Antoni Ribas,Roger S. Lo +15 more
TL;DR: It is shown that melanomas escape B-RAF(V600E) targeting not through secondary B-RF(V 600E) mutations but via receptor tyrosine kinase (RTK)-mediated activation of alternative survival pathway(s) or activated RAS-mediated reactivation of the MAPK pathway, suggesting additional therapeutic strategies.
Journal ArticleDOI
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Ravid Straussman,Teppei Morikawa,Kevin Shee,Michal Barzily-Rokni,Zhi Rong Qian,Jinyan Du,Ashli Davis,Margaret M. Mongare,Joshua Gould,Dennie T. Frederick,Zachary A. Cooper,Paul B. Chapman,David B. Solit,Antoni Ribas,Roger S. Lo,Keith T. Flaherty,Shuji Ogino,Jennifer A. Wargo,Todd R. Golub +18 more
TL;DR: It is found that stroma-mediated resistance is common, particularly to targeted agents, and the systematic dissection of interactions between tumours and their micro-environment can uncover important mechanisms underlying drug resistance.